Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
暂无分享,去创建一个
Jianying Zhou | Erdem Goker | Jun Zhao | Li Zhang | Zhenyu Ding | Nobuhiko Seki | Oleksandr Ivashchuk | Takuma Yokoyama | Kazuhiko Yamada | Tomonori Hirashima | Kazuo Kasahara | Giovanna Speranza | Tatsuo Ohira | Gilberto Lopes | Qing Zhou | Venceslau Hespanhol | Ying Cheng | Myung-Ju Ahn | Christina Galvez | Tomoya Kawaguchi | Hideo Saka | Lye Mun Tho | Yun Fan | Mei Hou | Buhai Wang | Andres Cardona | Daniel Ciurescu | Kaoru Kubota | Wei Li | Jorge Salas | Jacek Jassem | Jianxing He | Jianhua Chang | Tony Mok | T. Ohira | Y. Hosomi | Ying Cheng | O. Smaletz | M. Ahn | T. Mok | Yi-long Wu | Chih-Hsin Yang | H. Saka | C. Chiu | R. Ramlau | T. Hsia | J. Jassem | Q. Zhou | C. Barrios | S. Cicėnas | P. Ruff | Jianxing He | B. Karaszewska | B. Cho | T. Nishimura | D. Sirbu | K. Kubota | W. Su | Jian-hua Chang | A. Cardona | Kazuhisa Takahashi | C. Ferreira | M. Gumus | Wei Li | Y. Iwamoto | D. Betticher | Yilong Wu | L. Koubková | F. Franke | G. Lopes | S. How | C. Liam | D. Ganea | Li Zhang | Marius Žemaitis | V. Hespanhol | L. Bolotina | H. Galindo | L. Petruzelka | G. Ostoros | I. Vynnychenko | V. Sriuranpong | S. Qin | R. Juergens | Xin Zhang | Xiaoqing Liu | K. Kishi | Hiroshi Tanaka | Yong He | S. Cheng | T. Kurata | Yi Hu | Jun Zhao | Jie Wang | L. Havel | Jin Zhang | G. Lubiniecki | A. Zippelius | Caicun Zhou | Z. Ding | Gong-yan Chen | Jifeng Feng | Shun Lu | K. Hotta | F. Imamura | S. Sugawara | I. Bondarenko | Y. Fujisaka | E. Kalinka-Warzocha | Zhe Liu | N. Seki | H. Yoshioka | M. Şeker | A. Ochsenbein | C. Caglevic | T. Hirashima | N. Katakami | Byoung Chul Cho | Kazuhisa Takahashi | Te-Chun Hsia | Shun Lu | Fumio Imamura | Yasuhito Fujisaka | Takayasu Kurata | Fernando Barata | Nagio Takigawa | G. Speranza | Yi-Long Wu | Wu-Chou Su | Jie Wang | Virote Sriuranpong | Tony S K Mok | H. Freitas | Jana Jaal | V. Srimuninnimit | K. Aoe | Tuncay Goksel | Olga Ponomarova | Mircea Dediu | Doina Ganea | Daniel Betticher | Caicun Zhou | Paul Ruff | Chih-Hsin Yang | A. Horiike | I. Kudaba | D. Kowalski | H. Turna | G. Castro | K. Laktionov | D. Kush | G. Adamchuk | A. Alexandru | O. Altundag | A. Alyasova | O. Andrusenko | A. Araújo | O. Aren | O. Rodriguez | T. Ativitavas | Oscar Avendaño | F. Barata | C. Beato | Per Bergstrom | Michiel Botha | Sayeuri Buddu | H. Castro | F. C. Senler | Carlos Alexandre Sydow Cerny | A. Česas | G. Chan | Xi Chen | N. Cherciu | D. Ciurescu | G. Cohen | Marcos André Costa | P. Danchaivijitr | F. D. Angelis | S. Azevedo | M. Dediu | Ts Deliverski | P. Marchi | Flor de The Bustamante Valles | Boyan Doganov | L. Dreosti | R. Duarte | Regina Edusma-Dy | S. Emelyanov | M. Erman | Yun Fan | L. Fein | D. Fenton | G. Fernandes | Christina Galvez | N. Gil | G. Girotto | E. Goker | T. Goksel | Gonzalo Gomez Aubin | Luis Gomez Wolff | H. Griph | Jacqueline M. Hall | Greg Hart | C. Hernández | Chung-man. Ho | M. Hou | M. Ichiki | O. Ivashchuk | J. Jaal | Christa Jordaan | D. Kaen | N. Karaseva | A. Każarnowicz | K. Kasahara | T. Kato | T. Kawaguchi | J. H. Kim | V. Kolek | Marchela Koleva | P. Kolman | R. Kowalyszyn | K. Koynov | D. Ksienski | G. Kuusk | L. Kuzina | I. Laczó | G. Ladrera | G. Landers | S. Lazarev | G. Lerzo | Krzysztof Lesniewski- Kmak | Igor Lifirenko | O. Lipatov | S. Lo | Valeria Lopes | Karla Lopez | G. Martinengo | L. Mas | M. Matrosova | Rumyana Micheva | Z. Milanova | L. Miron | Tony Mok | M. Molina | S. Murakami | Y. Nakahara | Tien Quang Nguyen | Ronny Ohman | C. Ong | X. Ouyang | E. Ovchinnikova | O. Ozyılkan | Xuan Dung Pham | P. Picon | B. Pikó | A. Poltoratsky | O. Ponomarova | Patrice Popelkova | G. Purkalne | Bernardo Rappaport | Felipe Rey | E. Richardet | J. Roubec | A. Rusyn | J. Salas | M. Sandoval | L. Santos | T. Sawa | K. Seetalarom | Freddy Seolwane | Lucinda Shepherd | Sergii Shevnya | A. Shimada | Y. Shparyk | I. Sinielnikov | João Paulo Holanda Soares | A. Sookprasert | Zinaida Stara | W. Szpak | N. Takigawa | Jerry Tan Chun Bing | Q. Tang | P. Taranov | H. Tejada | L. Tho | Yoshitaro Torii | Dmytro Trukhyn | M. Turdean | G. Ursol | J. Vaňásek | M. Varela | M. Vallejo | Luis Vera | A. Victorino | T. Vlásek | Buhai Wang | Kai Wang | Kazuhiko Yamada | T. Yokoyama | T. Yokoyama | F. Yumuk | A. Zambrano | J. Zarbá | O. Zarubenkov | Jianying Zhou | Alfred Zippelius | Dariusz M Kowalski | Hande Turna | Vichien Srimuninnimit | Igor Bondarenko | Shukui Qin | Oleg Lipatov | Atsushi Horiike | Shunichi Sugawara | Eduardo Richardet | Nobuyuki Katakami | Joo Hang Kim | Hector Galindo | Oren Smaletz | Yong He | Fulden Yumuk | Luis Fein | Yi Hu | Chao-Hua Chiu | Hiroshi Tanaka | Jifeng Feng | Nina Karaseva | Gregory M Lubiniecki | Jin Zhang | Katsuyuki Hotta | Xiaoqing Liu | Kai Wang | Rodryg Ramlau | Leona Koubkova | Keisuke Aoe | Iveta Kudaba | Hande Z Turna | Gilberto Castro | Konstantin K Laktionov | Debra Kush | Grigory Adamchuk | Aurelia Alexandru | Ozden Altundag | Anna Alyasova | Orest Andrusenko | Antonio Araujo | Osvaldo Aren | Oscar Arrieta Rodriguez | Touch Ativitavas | Oscar Avendano | Carlos Henrique Barrios | Carlos Beato | Per Bergstrom | Larisa Bolotina | Michiel Botha | Sayeuri Buddu | Christian Caglevic | Hugo Castro | Filiz Cay Senler | Alvydas Cesas | Gee-Chen Chan | Gongyan Chen | Xi Chen | Susanna Cheng | Nelly Cherciu | Saulius Cicenas | Graham Cohen | Marcos Andre Costa | Pongwut Danchaivijitr | Flavia De Angelis | Sergio Jobim de Azevedo | Tsvetan Deliverski | Pedro Rafael Martins De Marchi | Boyan Doganov | Lydia Dreosti | Ricardo Duarte | Regina Edusma-Dy | Sergey Emelyanov | Mustafa Erman | David Fenton | Gustavo Fernandes | Carlos Ferreira | Fabio Andre Franke | Helano Freitas | Nuno Gil | Gustavo Girotto | Hakan Griph | Mahmut Gumus | Jacqueline Hall | Gregory Hart | Libor Havel | Carlos Hernandez Hernandez | Chung Man James Ho | Yukio Hosomi | Soon Hin How | Masao Ichiki | Yasuo Iwamoto | Christa Jordaan | Rosalyn Anne Juergens | Diego Kaen | Ewa Kalinka-Warzocha | Boguslawa Karaszewska | Andrzej Kazarnowicz | Terufumi Kato | Kazuma Kishi | Vitezslav Kolek | Marchela Koleva | Petr Kolman | Ruben Kowalyszyn | Dariusz Kowalski | Krassimir Koynov | Doran Ksienski | Gerli Kuusk | Lyudmila Kuzina | Ibolya Laczo | Guia Elena Imelda Ladrera | Konstantin Laktionov | Gregory Landers | Sergey Lazarev | Guillermo Lerzo | Krzysztof Lesniewski Kmak | Chong Kin Liam | Igor Lifirenko | Zhe Liu | Sing Hung Lo | Valeria Lopes | Karla Lopez | Gaston Martinengo | Luis Mas | Marina Matrosova | Rumyana Micheva | Zhasmina Milanova | Lucian Miron | Matias Molina | Shuji Murakami | Yasuharu Nakahara | Takashi Nishimura | Adrian Ochsenbein | Ronny Ohman | Choo Khoon Ong | Gyula Ostoros | Xuenong Ouyang | Elena Ovchinnikova | Ozgur Ozyilkan | Lubos Petruzelka | Pablo Picon | Bela Piko | Artem Poltoratsky | Patrice Popelkova | Gunta Purkalne | Bernardo Rappaport | Felipe Rey | Jaromir Roubec | Andrii Rusyn | Mario Sandoval | Lucas Santos | Toshiyuki Sawa | Kasan Seetalarom | Mesut Seker | Freddy Seolwane | Lucinda Shepherd | Sergii Shevnya | Andrea Kazumi Shimada | Yaroslav Shparyk | Ivan Sinielnikov | Daniela Sirbu | Joao Paulo Holanda Soares | Aumkhae Sookprasert | Zinaida Stara | Waldemar Szpak | Qiyou Tang | Pavel Taranov | Hermes Tejada | Yoshitaro Torii | Dmytro Trukhyn | Maria Turdean | Grygoriy Ursol | Jaroslav Vanasek | Mirta Varela | Marcela Vallejo | Luis Vera | Ana-Paula Victorino | Tomas Vlasek | Ihor Vynnychenko | Yilong Wu | Toshihide Yokoyama | Hiroshige Yoshioka | Angela Zambrano | Juan Jose Zarba | Oleg Zarubenkov | Marius Zemaitis | Xin Zhang | M. Seker | Qing Zhou | F. Senler | Yi‐Long Wu | E. Kalinka‐Warzocha | S. Lu | Chih‐Hsin Yang | L. Petruželka | Olga Ponomarova | Oscar Avendano | J. Kim | Gongyan Chen | L. Shepherd | Mario Sandoval
[1] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[2] Peter M. Ellis,et al. First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] Xueqing Liu,et al. Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immunome evaluation , 2020, Oncology reports.
[4] Rafal Dziadziuszko,et al. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[5] M Nurminen,et al. Comparative analysis of two rates. , 1985, Statistics in medicine.
[6] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[7] L. Gianni,et al. Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer , 2017, Front. Med..
[8] C. Gridelli,et al. Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies , 2017, PloS one.
[9] Lianjun Lin,et al. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors , 2020, Disease markers.
[10] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[11] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[12] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[13] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[14] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[15] Maobai Liu,et al. Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review , 2020, Cancer management and research.
[16] B. Efron. The Efficiency of Cox's Likelihood Function for Censored Data , 1977 .
[17] A. Tafreshi,et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[18] Serafino Pantano,et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.
[19] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[20] K. Harrington,et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.
[21] A. Tafreshi,et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[23] S. Novello,et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[24] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.
[25] A. Gemma,et al. F1000 highlights , 2010 .
[26] C. Obasaju,et al. PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[27] T. Holzer,et al. Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer , 2020, Scientific Reports.
[28] J. S. D. Cani,et al. Group sequential designs using a family of type I error probability spending functions. , 1990, Statistics in medicine.
[29] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[30] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[31] M. Dolled-Filhart,et al. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer , 2016, Applied immunohistochemistry & molecular morphology : AIMM.
[32] H. Rammensee,et al. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire , 2020, Nature Reviews Clinical Oncology.